Nattokinase vs Omega-3 (EPA/DHA)
A side-by-side research comparison of Nattokinase and Omega-3 (EPA/DHA) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Nattokinase | Omega-3 (EPA/DHA) |
|---|---|---|
| Full name | Nattokinase (Subtilisin NAT) | Omega-3 Fatty Acids (EPA + DHA) |
| Category | Cardiovascular | Cardiovascular |
| Status | Dietary supplement | Dietary supplement / FDA-approved (Rx fish oil) |
| Mechanism | Directly degrades fibrin in blood clots via proteolytic activity. Also activates endogenous tissue plasminogen activator (tPA) and suppresses plasminogen activator inhibitor-1 (PAI-1), enhancing the body's own fibrinolytic system. | EPA/DHA incorporate into cell membranes, displacing arachidonic acid and reducing pro-inflammatory eicosanoid production. Generate resolvins and protectins for active inflammation resolution. Activate PPARγ and inhibit NF-κB. |
| Molecular weight | ~27,728 Da | EPA: 302.45 Da, DHA: 328.49 Da |
| Half-life | ~8-12 hours (fibrinolytic activity) | ~48-72 hours (membrane incorporation) |
| Bioavailability | Oral absorption confirmed; survives GI tract | Triglyceride form: ~70%; ethyl ester: ~30-40%; phospholipid (krill): ~85% |
| Typical dose | 2000-4000 FU (fibrinolytic units) | 2-4g combined EPA+DHA |
| Frequency | Daily on empty stomach | Daily with meals |
| Route | Oral capsule | Oral (softgel, liquid) |
Nattokinase reported benefits
- Fibrin clot dissolution
- Blood pressure reduction
- Improved blood viscosity
- Reduced DVT risk
- Atherosclerosis prevention
- Natural anticoagulant alternative
Omega-3 (EPA/DHA) reported benefits
- Triglyceride reduction (25-45%)
- Anti-inflammatory (SPM production)
- Cardiac rhythm stabilization
- Brain and cognitive support
- Joint inflammation reduction
- Membrane fluidity optimization
Related comparisons
Research and educational reference only. Not medical advice.